GCL is composed of a catalytic (GCLC, Mr ~73 kDa) and a modifier (GCLM, Mr ~31 kDa) subunit [32] (summarized in Fig
Enhance your infusion with targeted boosts
1 and Supplementary Sections 4 and 5) and 96 clinical studies (Tables 16, Fig
This highlights the need to consider the risks and benefits of these medications
Stay hydrated - GLP-1 medications can reduce thirst signals
Dual-Action Mechanism GLP-1 Receptor Activation Increases insulin secretion in response to glucose Slows gastric emptying, keeping patients full longer Reduces glucagon secretion, stabilizing blood sugar GIP Receptor Activation Enhances insulin sensitivity and beta-cell function Supports fat metabolism and energy balance Amplifies GLP-1 effects for superior metabolic results Together, these mechanisms promote sustained weight loss, stabilize blood sugar, and improve metabolic function What to Expect with GLP-1 & GIP Treatment Patients may experience reduced appetite and mild nausea as their body adjusts